3BDO
SIGMA/SML1687 - ≥98% (HPLC)
Synonym: 3-
CAS Number: 890405-51-3
Empirical Formula (Hill Notation): C18H17NO5
Molecular Weight: 327.33
Linear Formula: C18H17NO5
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | colorless to light brown |
| form | oil |
| InChI | 1S/C18H17NO5/c20-18-14(10 |
| InChI key | AXPZIVKEZRHGAS-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | O=C1OC(COC2=C([N+]([O-])= |
| storage temp. | 2-8°C |
| Application: | 3BDO has been used to investigate the potential effects of metformin on inflammatory lung injury. |
| Biochem/physiol Actions: | 3BDO is a cell-permeable, orally bioavailable, non-toxic butyrolactone derivative that is shown to competitively bind FKBP1A (FK506-binding protein 1A, 12 kDa) in a reversible manner, and suppress autophagy via the mTOR pathway. 3BDO inhibits both LPS- and oxLDL-induced autophagy in HUVECs, increases TIA1 phosphorylation, and reduces autophagosomes number. It is reported to be brain permeant, and significantly decreases atherosclerosis development in apoE-/- mice (100 mg/kg, q.d., p.o.). 3BDO increases IDE and neprilysin levels, lowers amyloid-β deposition in an AβPP/PS1 transgenic mouse model of Alzheimer′s disease, and alleviates memory deficits. |
| Biochem/physiol Actions: | An orally bioavailable, brain-permeant suppressor of mTOR-mediated autophagy; reduces Aβ levels and prevents cognitive deficits in AβPP/PS1 mouse model. |
| Biochem/physiol Actions: | An orally bioavailable, brain-permeant suppressor of mTOR-mediated autophagy; reduces Aβ levels and prevents cognitive deficits in AβPP/PS1 mouse model. 3-benzyl-5-[(2-nitropheno |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |